Alyeska Investment Group
LAB icon

Alyeska Investment Group’s Standard BioTools LAB Stock Holding History

Alyeska Investment Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-515,964
Closed -$2.33M – 791
2021
Q1 		$2.33M Sell
515,964
-370,103
-42% -$2.03M 0.03% 447
2020
Q4 		$5.32M Buy
886,067
+323,567
+58% +$2.13M 0.08% 259
2020
Q3 		$4.18M Buy
562,500
+220,895
+65% +$1.52M 0.06% 281
2020
Q2 		$1.37M Buy
+341,605
New +$1.19M 0.02% 383
2020
Q1 		– Sell
-1,122,066
Closed -$3.9M – 428
2019
Q4 		$3.9M Buy
+1,122,066
New +$3.95M 0.05% 245

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alyeska Investment Group's LAB Position: Q2 2021 in Review

Alyeska Investment Group sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 515,964 shares — an estimated $2.33M sold.

Alyeska Investment Group first reported a position in LAB in Q4 2019 and held it in 5 quarters. The position peaked at $5.32M in Q4 2020. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Alyeska Investment Group reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 515,964 Standard BioTools shares in Q2 2021, an estimated $2.33M.
  • Alyeska Investment Group first reported a position in Standard BioTools in Q4 2019 and held it in 5 quarters.
  • Alyeska Investment Group's Standard BioTools position peaked at $5.32M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.